Pasithea Therapeutics Corp. — Director's Dealing 2023

Jul 3, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2023-07-03

Reporting Person: Currie Graeme Martin (Chief Development Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$0.491	2033-02-23	Common Stock, par value $0.0001 per share (300000)		Direct

Footnotes

F1: 33% of the shares underlying the option vest on June 30, 2023, and the remaining shares will vest in equal quarterly installments for each of the two years thereafter, in each case subject to the Reporting Person continuing to be employed or otherwise provide services to the Issuer on each vesting date.